Scynexis Inc revenue
Scynexis Inc's revenue was $20.6m in fiscal 2025, up 449.9% on the year before. Since fiscal 2013 ($16.9m) it has grown at a compound 1.7% a year. Over the last twelve months it was $19.2m.
Revenue history
| Fiscal year | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 5 | 140 | 4 | 21 | 19 |
| Growth on the year before | — | −30.4% | −97.8% | 0.0% | 0.0% | 0.0% | −52.9% | −100.0% | — | −61.3% | +>999% | −97.3% | +449.9% | — |
| Gross profit | 1 | 4 | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross margin | 3.3% | 30.5% | — | — | — | — | — | — | — | — | — | — | — | — |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Licenses and services | $19.2M | 93.0% | ▲ 411.4% |
| Products | $1.4M | 7.0% | — |
From Scynexis Inc's 10-K filed March 4, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Scynexis Inc | $19.2m | 489.8% | -47.9% |
| Celularity Inc | $18.7m | -58.1% | 7.2% |
| Cytomx Therapeutics, Inc. | $18.3m | -87.0% | -38.7% |
| Proqr Therapeutics N.V. | $18.0m | -12.1% | — |
| Janux Therapeutics, Inc. | $24.0m | 5367.0% | 45.7% |
| Keros Therapeutics, Inc. | $14.9m | -93.6% | — |
Compare with peers
- Celularity Inc revenue
- Cytomx Therapeutics, Inc. revenue
- Proqr Therapeutics N.V. revenue
- Janux Therapeutics, Inc. revenue
- Keros Therapeutics, Inc. revenue
Head to head: CELU vs SCYXCTMX vs SCYXPRQR vs SCYX
More: Biotechnology stocks compared, Health Care sector, rankings of US companies